The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / With Apps & Remote Medicine, Japan Offers Glimpse of Doctor Visits in Post-COVID-19 Era

With Apps & Remote Medicine, Japan Offers Glimpse of Doctor Visits in Post-COVID-19 Era

July 13, 2020 • By Kaori Kaneko & Izumi Nakagawa

  • Tweet
  • Email
Print-Friendly Version / Save PDF

TOKYO (Reuters)—The coronavirus crisis has prompted Japan to ease regulations on remote medical treatment, creating an opening for tech companies and offering a glimpse of the future of healthcare in the world’s most rapidly aging society.

You Might Also Like
  • Telemedicine Company Wins Order Putting Texas Remote Treatment Rule on Hold
  • Japan PM’s Advisers Urge Annual Review of Drug Prices
  • Tight RA Control Via Telemedicine Noninferior to Conventional Clinic Visits

As coronavirus cases spiked in April, Japan temporarily eased restrictions on remote medical care, allowing doctors to conduct first-time visits online or by telephone and expanding the number of illnesses that can be treated remotely.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The changes mark a potential shake-up in one of the world’s biggest medical markets, which has lagged countries like Australia, China and the U.S. in telemedicine. The reforms could also help Japan grapple with both a skyrocketing healthcare burden and few doctors in rural areas.

Previously Japanese doctors were only allowed to treat recurring patients remotely, and for a limited number of diseases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The rapid pace of change caught executives at Line Corp. off guard, forcing Japan’s most popular social networking service to accelerate plans for the rollout of its Line Healthcare business in the coming months.

“The effect that COVID-19 brought was a huge innovation in the healthcare industry,” says Shinichiro Muroyama, representative director of Line Healthcare. “The situation has totally changed, much more rapidly than we thought.”

Line, which says it has 84 million users in Japan, aims to link doctors and patients by video.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Homegrown medical start-ups, such as Medley Inc. and MICIN Inc., say they have also seen a surge in demand. Both companies offer application services for appointments, video consultations and payments.

Telehealth or telemedicine refers to technology that includes online consultations, cloud-based medical records, remote monitoring of patients and use of artificial intelligence to screen for diseases.

Japan’s market for such technology is set to grow by 60% to nearly 20 billion yen ($185 million; $1 = 107.5200 yen) in the five years to March 2024, according to the Yano Research Institute.

Japanese Prime Minister Shinzo Abe has made deregulating the medical industry part of his growth strategy.

Better Outcomes
So Ishii, a doctor who runs a clinic in Tokyo that started offering telemedicine in 2017, has seen a jump in online consultations since the outbreak, with 600 patients using the service as of mid-June compared to 400 two months earlier.

Dr. Ishii says telehealth could lead to better treatment for patients with lifestyle-related diseases that require continuous attention because it gave them easier access to doctors. Such ailments typically include diabetes and high-blood pressure.

“Ideally, medical care should be designed to provide necessary support for patients regardless of whether it is online or on site,” he says.

About 16,100 Japanese medical institutions excluding dentists—nearly 15% of all such facilities—offered remote medical services, including by telephone, as of early July, according to the health ministry.

That marks substantial growth since July 2018, when only 970 medical institutions were registered to offer online care.

Still, the health ministry has not decided whether to make the changes permanent, while the national medical association is less than enthusiastic, citing concerns about misdiagnosis.

“We should be extremely cautious about using evidence drawn from telemedicine in the emergency situation for consideration of how it should be after the coronavirus infection wanes,” Japan Medical Association President Toshio Nakagawa tells Reuters. He was vice-president at the time of the interview.

Analysts say telemedicine can also put smaller clinics at a financial disadvantage.

Goichiro Toyoda, representative director and a medical doctor at Medley, agrees doctors can better check first-time patients in person but says telemedicine suits patients who want second opinions, have trouble visiting hospitals or need long-term treatments.

“Telemedicine will not replace face-to-face treatment,” says Dr. Toyoda. “But I’ve been stressing the importance of it becoming an option.”

Pages: 1 2 | Multi-Page

Filed Under: Technology Tagged With: International, Japan, patient care, Technology, telemedicine

You Might Also Like:
  • Telemedicine Company Wins Order Putting Texas Remote Treatment Rule on Hold
  • Japan PM’s Advisers Urge Annual Review of Drug Prices
  • Tight RA Control Via Telemedicine Noninferior to Conventional Clinic Visits
  • Telehealth Visits May Be an Option After Surgery

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)